Online Pet Medications & Pet Supplies

Inflacam Dog 1.5Mg 42Ml

Category: I

Select Option
Inflacam Dog 1.5Mg 42Ml - £ 9.98
QTY:
Product REF: VIINF05
Inflacam Dog 1.5Mg 15Ml - £ 5.58
QTY:
Product REF: VIINF04
Inflacam Dog 1.5Mg 100Ml - £ 16.52
QTY:
Product REF: VIINF06
Inflacam Dog 1.5Mg 15Ml - £ 5.58
QTY:
Product REF: VIINF04

Total Price: £0.00


Vat Rate: 20%

Prescription Required



Target species Dogs Indications for use Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. Contra-indications Do not use in pregnant or lactating animals. Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs less than 6 weeks of age. Special warnings for each target species None Special precautions for use Special precautions for use in animals Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of renal toxicity. Special precautions to be taken by the person administering the veterinary medicinal product to animals People with known hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs) should avoid contact with the veterinary medicinal product. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Adverse reactions Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. In very rare cases haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported. These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought. Use during pregnancy, lactation or lay The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). Interactions Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. Inflacam must not be administered in conjunction with other NSAIDs or glucocorticosteroids. Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacokinetic properties of the veterinary products used previously.

Our Standard Delivery - £6.75

Royal Mail Tracked 24 (Signed For)

  • Next business day service
  • Compensation cover up to £100
  • Signature on delivery

 

Any orders placed after close of business on Thursday will not be delivered until Tuesday

 

 

 

Our Express Delivery - £10.45

Royal Mail Special Delivery Guaranteed by 1pm

  • Next business day service
  • Insured up to £500
  • Signature on delivery

 

Please note that all chilled deliveries must be sent on an Express service.

Chilled orders placed after close of business on Wednesday will not be despatched until Monday

You must be logged in to write review
Category POM-V
Temperature Ambient
MA/VM/EU No: 08749/5010
Species
  • dogs
VMD Link https://www.vmd.defra.gov.uk/ProductInformationDatabase/product/A008276
NOAH Link
Dosage Amounts to be administered and administration route Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. For longer term treatment, once clinical response has been observed (after ≥ 4 days), the dose of Inflacam can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time. Particular care should be taken with regard to the accuracy of dosing. Shake well before use. To be administered orally either mixed with food or directly into the mouth. The suspension can be given using the Inflacam measuring syringe provided in the package. The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus for initiation of the therapy on the first day, twice the maintenance volume will be required. A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent. Avoid introduction of contamination during use. Overdose In case of overdose symptomatic treatment should be initiated.
Withdrawals